Received Oct 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RVX | ROTAVIRUS (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | UNK | — |
had my shot in mid. October of 2023 by Dec. I had RSV in December; Suspected vaccination failure; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received RSVPreF3 adjuvanted (RSV vaccine) for prophylaxis. In OCT-2023, the patient received RSV vaccine. In DEC-2023, between 2 and 3 months after receiving RSV vaccine, the patient experienced vaccination failure (Verbatim: Suspected vaccination failure) (serious criteria GSK medically significant and clinically significant/intervention required) and respiratory syncytial virus infection (Verbatim: had my shot in mid. October of 2023 by Dec. I had RSV in December) (serious criteria hospitalization and clinically significant/intervention required). The outcome of the vaccination failure and respiratory syncytial virus infection were not reported. It was unknown if the reporter considered the vaccination failure and respiratory syncytial virus infection to be related to RSV vaccine. The company considered the vaccination failure and respiratory syncytial virus infection to be unrelated to RSV vaccine. Additional Information: GSK Receipt Date: 22-OCT-2025 This case was reported by a patient via interactive digital media. The patient had his/her RSV shot in mid-OCT of 2023 by DEC the patient had RSV and ended up with a track feeding tube they did not think, and the patient would made it, so the patient was sent to a hospital. The patient refused to give up, and it could have been worse had the patient not had shot. The batch number was not provided, and unable to contact the reporter. This case was considered as suspected vaccination failure since the details regarding laboratory confirmation of respiratory syncytial virus infection were unknown at the time of reporting.; Sender's Comments: A case of Vaccination failure and Respiratory syncytial virus infection, between 2 and 3 months after receiving RSV vaccine, in a patient. Based on the available information a?possible causality that the event was caused by the GSK product cannot be ascertained. Consent for further follow-up has not been received.